## **ACTIN** Report (research use only)

PATIENT
EXAMPLE-LUNG-02
REPORT DATE
01-Nov-2024

Gender: Male | Birth year: 1965 | WHO: 1

Tumor: Lung - Squamous cell carcinoma | Lesions: Liver, Lung | Stage: III

## Summary

#### **Clinical summary**

Relevant systemic treatment history 6/2023-6/2024 Carboplatin+Pemetrexed continued with Pemetrexed

maintenance

7/2024-8/2024 Docetaxel

Relevant other oncological history None

Previous primary tumor None

Relevant non-oncological history 1/2020 Acute myocardial infarction

1/2000 Bipolar disorder

#### Recent molecular results

#### NGS Lung Panel 1.2 (15-Sep-2024)

Biopsy location Lung

Molecular tissue of origin prediction Unknown

Tumor mutational load / burden Unknown / TMB low (8)

Microsatellite (in)stability

Stable

HR status

Proficient

High driver mutations PIK3CA E545K

Amplified genes None

Deleted genes TP53, KEAP1

Homozygously disrupted genes

Gene fusions

None

Virus detection

None

Potentially actionable events with medium/low driver:

None

IHC results PD-L1: Score < 1%

#### Example trials that are open and potentially eligible (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 05	Dose expansion - monotherapy -	PIK3CA E545K	History of Acute myocardial infarction
PICKME3CA	NSCLC		

### Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01	Dose escalation - monotherapy		None
IEMOEN			

# **ACTIN Report (research use only)**

PATIENT
EXAMPLE-LUNG-02
REPORT DATE
01-Nov-2024

## **Trial Matching Summary**

Example trials and cohorts that are potentially eligible, but are closed (1)

Trial	Cohort	Molecular	Warnings
METC 01	Dose expansion - monotherapy		None
IEMOEN			

### Example trials and cohorts that are open but considered ineligible (5)

Trial	Cohort	Molecular	Ineligibility reasons
METC 05 PICKME3CA	Dose expansion - monotherapy - Other cancer types	PIK3CA E545K	Has tumor belonging to DOID term(s) lung non-small cell carcinoma
METC 02 KAYRAS	Applies to all cohorts below	None	G12D not detected in KRAS
	Dose expansion - monotherapy - Colorectum		No colorectal cancer
	Dose expansion - monotherapy - NSCLC		
METC 03 NO-SEE797ES	Dose escalation - monotherapy		No variants in codon(s) C797 in EGFR
METC 04 TEDR1	Lung cancer C797S cohort		C797S not detected in EGFR

Open cohorts with no slots available are shown in grey.

Example trials and cohorts that are closed and considered ineligible (0)

None

Example trials and cohorts that are not evaluable or ignored (0)

None